Want to see MRK full AI Analyst Report?

Merck & Company (MRK) Stock Forecast & Price Target

15,113 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRK Analyst Ratings

Moderate Buy

15 Buy

6 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$160.00

▲(2.27% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $160.00 with a high forecast of $180.00 and a low forecast of $105.00. The average price target represents a 2.27% change from the last price of $156.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","181":"$181","106.75":"$106.8","131.5":"$131.5","156.25":"$156.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,106.75,131.5,156.25,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,143.81,146.59384615384616,149.3776923076923,152.16153846153847,154.94538461538463,157.72923076923078,160.51307692307694,163.29692307692306,166.08076923076922,168.86461538461538,171.64846153846153,174.4323076923077,177.21615384615384,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,143.81,145.0553846153846,146.30076923076922,147.54615384615386,148.79153846153847,150.03692307692307,151.28230769230768,152.52769230769232,153.77307692307693,155.01846153846154,156.26384615384615,157.50923076923078,158.7546153846154,{"y":160,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,143.81,140.82461538461538,137.83923076923077,134.85384615384615,131.86846153846153,128.8830769230769,125.89769230769231,122.91230769230769,119.92692307692307,116.94153846153847,113.95615384615385,110.97076923076924,107.98538461538462,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":87.558,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.527,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.925,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.131,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.077,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.954,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.273,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.705,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.676,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.634,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.435,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.98,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.81,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$180.00

Average Price Target$160.00

Lowest Price Target$105.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

RBC Capital

$145

Hold

-7.32%

Downside

Reiterated

10/16/26

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

Geoff Meacham

Citi

$145

Hold

-7.32%

Downside

Reiterated

10/16/26

Merck price target raised to $145 from $125 at CitiMerck price target raised to $145 from $125 at Citi

Mohit Bansal

Wells Fargo

$165

Buy

5.47%

Upside

Reiterated

10/15/26

Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Merck & Company (NYSE: MRK) and Celldex (NASDAQ: CLDX)

Evan Seigerman

BMO Capital

$170

Buy

8.66%

Upside

Reiterated

10/12/26

Merck & Company (MRK) Gets a Buy from BMO Capital

Emily Field

Barclays

$150

Buy

-4.12%

Downside

Reiterated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

Daina Graybosch

Leerink Partners

$161

Buy

2.91%

Upside

Reiterated

10/12/26

Merck & Company (MRK) Gets a Buy from Leerink Partners

Carter Gould

Cantor Fitzgerald

$145

Hold

-7.32%

Downside

Reiterated

10/11/26

Merck & Company (MRK) Receives a Hold from Cantor Fitzgerald

Jason Gerberry

Bank of America Securities

$166→$163

Buy

4.19%

Upside

Reiterated

10/09/26

Merck price target lowered to $163 from $166 at BofAMerck price target lowered to $163 from $166 at BofA

Michael Yee

UBS

$175

Buy

11.86%

Upside

Reiterated

10/09/26

Merck & Company (MRK) Receives a Buy from UBS

Terence Flynn

Morgan Stanley

$177

Buy

13.14%

Upside

Reiterated

10/07/26

Merck & Company (MRK) Gets a Buy from Morgan Stanley

Chris Schott

J.P. Morgan

$150→$165

Buy

5.47%

Upside

Reiterated

10/05/26

Merck price target raised to $165 from $150 at JPMorganMerck price target raised to $165 from $150 at JPMorgan

Asad Haider

Goldman Sachs

$160

Buy

2.27%

Upside

Reiterated

09/30/26

Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating

Louise Chen

Scotiabank

$155→$180

Buy

15.05%

Upside

Reiterated

09/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Steve Scala

TD Cowen

$137→$155

Hold

-0.93%

Downside

Reiterated

09/22/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Nico Chen

DBS

$180

Buy

15.05%

Upside

Reiterated

09/11/26

DBS Keeps Their Buy Rating on Merck & Company (MRK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

RBC Capital

$145

Hold

-7.32%

Downside

Reiterated

10/16/26

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

Geoff Meacham

Citi

$145

Hold

-7.32%

Downside

Reiterated

10/16/26

Merck price target raised to $145 from $125 at CitiMerck price target raised to $145 from $125 at Citi

Mohit Bansal

Wells Fargo

$165

Buy

5.47%

Upside

Reiterated

10/15/26

Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Merck & Company (NYSE: MRK) and Celldex (NASDAQ: CLDX)

Evan Seigerman

BMO Capital

$170

Buy

8.66%

Upside

Reiterated

10/12/26

Merck & Company (MRK) Gets a Buy from BMO Capital

Emily Field

Barclays

$150

Buy

-4.12%

Downside

Reiterated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

Daina Graybosch

Leerink Partners

$161

Buy

2.91%

Upside

Reiterated

10/12/26

Merck & Company (MRK) Gets a Buy from Leerink Partners

Carter Gould

Cantor Fitzgerald

$145

Hold

-7.32%

Downside

Reiterated

10/11/26

Merck & Company (MRK) Receives a Hold from Cantor Fitzgerald

Jason Gerberry

Bank of America Securities

$166→$163

Buy

4.19%

Upside

Reiterated

10/09/26

Merck price target lowered to $163 from $166 at BofAMerck price target lowered to $163 from $166 at BofA

Michael Yee

UBS

$175

Buy

11.86%

Upside

Reiterated

10/09/26

Merck & Company (MRK) Receives a Buy from UBS

Terence Flynn

Morgan Stanley

$177

Buy

13.14%

Upside

Reiterated

10/07/26

Merck & Company (MRK) Gets a Buy from Morgan Stanley

Chris Schott

J.P. Morgan

$150→$165

Buy

5.47%

Upside

Reiterated

10/05/26

Merck price target raised to $165 from $150 at JPMorganMerck price target raised to $165 from $150 at JPMorgan

Asad Haider

Goldman Sachs

$160

Buy

2.27%

Upside

Reiterated

09/30/26

Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating

Louise Chen

Scotiabank

$155→$180

Buy

15.05%

Upside

Reiterated

09/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Steve Scala

TD Cowen

$137→$155

Hold

-0.93%

Downside

Reiterated

09/22/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Nico Chen

DBS

$180

Buy

15.05%

Upside

Reiterated

09/11/26

DBS Keeps Their Buy Rating on Merck & Company (MRK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KNSAKiniksa Pharmaceuticals

OMCLOmnicell

AXGNAxoGen

ONCBeOne Medicines

AHCOAdaptHealth

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months

Asad HaiderGoldman Sachs

Success Rate

12/14 ratings generated profit

Average Return

+10.63%

Copying Asad Haider's trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +10.63% per trade.

1 Year

Asad HaiderGoldman Sachs

Success Rate

13/14 ratings generated profit

Average Return

+36.70%

Copying Asad Haider's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +36.70% per trade.

2 Years

Vamil DivanGuggenheim

Success Rate

19/20 ratings generated profit

Average Return

+35.76%

Copying Vamil Divan's trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +35.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRK has received 47 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 160.00.

Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.09 with a range of $1.80 to $2.26. The previous quarter’s EPS was -$0.13. MRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $17.29B with a range of $16.75B to $17.63B. The previous quarter’s sales results were $16.58B. MRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MRK has Performed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 160.00.

What is MRK’s upside potential, based on the analysts’ average price target?

Merck & Company has 2.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRK a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.

What is Merck & Company’s price target?

The average price target for Merck & Company is 160.00. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $180.00 ,the lowest forecast is $105.00. The average price target represents 2.27% Increase from the current price of $156.45.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of MRK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Merck & Company (MRK) Stock Forecast & Price Target

MRK Analyst Ratings

MRK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

MRK Analyst Recommendation Trends

MRK Financial Forecast

MRK Earnings Forecast

MRK Sales Forecast

MRK Stock Forecast FAQ

Detailed List of Analyst Forecasts